Arcellx, Inc.

As of May 8, 2023, Arcellx, Inc. is considered risky and overvalued due to its high Price to Book Value of 9.00, negative EV to EBIT of -16.87, and troubling ROE of -38.96%, despite showing strong short-term performance compared to the S&P 500.

As of May 8, 2023, Arcellx, Inc. is considered a risky investment due to its overvaluation indicated by a high Price to Book Value of 9.00, negative EV to EBIT and EV to EBITDA ratios, a concerning Return on Equity of -38.96%, and underperformance compared to the S&P 500, with a year-to-date decline of 17.04%.

As of June 11, 2025, Arcellx, Inc. shows a mildly bearish trend, indicated by daily moving averages and Bollinger Bands, while the MACD presents mixed signals, suggesting a cautious approach.

Arcellx, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $8 million and a net loss of $62 million as of March 2025. Key financial metrics include a market cap of $3.47 billion, a P/E ratio of NA, and a dividend yield of 0%.

As of Jun 18, Arcellx, Inc. has a market capitalization of $3.47 billion, with net sales of $76.81 million and a net profit of -$162.42 million over the last four quarters. As of Dec 24, shareholder's funds are $454.79 million and total assets are $711.33 million.